Axcella to Present at J.P. Morgan Healthcare Conference
January 09 2020 - 8:00AM
Business Wire
Presentation and webcast to take place at 11:30
a.m. ET on January 16
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company
focused on leveraging endogenous metabolic modulators (EMMs) to
pioneer a new approach for treating complex diseases and improving
health, today announced that President and CEO Bill Hinshaw will be
presenting at the 38th Annual J.P. Morgan Healthcare Conference in
San Francisco on January 16, 2020 at 8:30 a.m. PT (11:30 a.m. ET).
This presentation will include a discussion of interim findings
from the company’s ongoing clinical study of AXA1125 and AXA1957,
as well as the company’s expected 2020 milestones.
A live audio webcast of the presentation will be available on
the “Investors & News” section of the company’s website,
www.axcellahealth.com. A replay will also be available on Axcella’s
website for 30 days following the presentation.
About Axcella’s Ongoing Clinical Studies
Each of the company’s ongoing clinical studies are being
conducted as non-investigational new drug (IND) application
clinical studies under U.S. Food and Drug Administration
regulations and guidance supporting research with food. These
studies evaluate product candidates for safety, tolerability and
effects on the normal structures and functions in humans, including
in individuals with disease. They are not designed or intended to
evaluate a product candidate’s ability to diagnose, cure, mitigate,
treat or prevent a disease. If Axcella decides to further develop a
product candidate as a potential therapeutic, as is the case with
AXA1665 and AXA1125/1957, subsequent studies will be conducted
under an IND.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of
disclosing material nonpublic information and for complying with
its disclosure obligations under Regulation FD. Such disclosures
will be included on the company’s website in the “Investors and
News” section. Accordingly, investors should monitor such portions
of the company’s website, in addition to following its press
releases, SEC filings and public conference calls and webcasts.
About Axcella
Axcella is a clinical-stage biotechnology company focused on
leveraging endogenous metabolic modulators (EMMs) to pioneer a new
approach for treating complex diseases and improving health. The
company’s product candidates are comprised of EMMs that are
engineered in distinct combinations and ratios to simultaneously
impact multiple biological pathways. Axcella’s pipeline includes
lead therapeutic candidates for overt hepatic encephalopathy (OHE)
and non-alcoholic steatohepatitis (NASH). Additional muscle- and
blood-related programs are in earlier-stage development. For more
information, please visit www.axcellahealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200109005308/en/
Company/Investor Contact Jason Fredette
jfredette@axcellahealth.com 857.320.2236
Media Contact Azeem Zeekrya HDMZ azeem.zeekrya@hdmz.com
312-506-5244
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Apr 2023 to Apr 2024